Effects of ipragliflozin in patients with type 2 diabetes mellitus, arterial hypertension and left ventricular diastolic dysfunction in a short-term prospective study

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective: Evaluation of the effect of ipragliflozin on metabolic, hemodynamic parameters, diastolic function (DF) of the left ventricle (LV), adherence to therapy and quality of life of patients with type 2 diabetes mellitus (DM2), arterial hypertension (AH) and left ventricle diastolic dysfunction (LVDD).

Materials and methods: Prospective cohort comparative study was conducted at the Department of Internal Medicine and Family Medicine of Postgraduate Education, Omsk State Medical University. In accordance with the inclusion/exclusion criteria, 2 groups of 30 patients (14/30 men) with DM2, AH and DDLV were formed. Group 1 received ipragliflozin 50 mg per day in monotherapy or in combination with other hypoglycemic drugs. Patients underwent general clinical, laboratory and instrumental studies, physical working capacity test, assessment of quality of life, adherence to therapy and tolerability of the drug.

Results: During the follow-up of 30 patients with DM2, AH and LVDD, who received ipragliflozin, an improvement in metabolic parameters was noted: a decrease in body weight, body mass index (BMI), waist circumference (WC), triglyceride, uric acid, alanine aminotransferase (ALT), glucose, glycated hemoglobin (HbA1c) levels, hemodynamic parameters (a decrease in office BP, daytime BP variability (DBP), nighttime mean BP (NMBP), LV DF, subjective status and quality of life of patients. No serious adverse events or early withdrawal of participants from the study for this reason were registered.

Conclusion: Therapy with ipragliflozin for 12 weeks in a group of patients with DM2, AH and LVDD is accompanied by positive dynamics of metabolic status indicators, BP levels, LVDF with a decrease in the total proportion of people with LVDD, the N-terminal propeptide of natriuretic hormone (NT-proBNP) level in combination with improvement of subjective status and quality of life of patients with good tolerability of therapy and sufficient adherence to treatment.

Full Text

Restricted Access

About the authors

Svetlana S. Safronova

Omsk State Medical University

Email: safronova.sv77@gmail.com
ORCID iD: 0000-0001-5852-2782

Teaching Assistant, Department of Internal Medicine and Family Medicine of Postgraduate Education

Russian Federation, Omsk

Inna V. Druk

Omsk State Medical University

Author for correspondence.
Email: drukinna@yandex.ru
ORCID iD: 0000-0001-8317-7765

Dr. Sci. (Med.), Associate Professor, Head of the Department of Internal Medicine and Family Medicine of Postgraduate Education

Russian Federation, Omsk

Olesya I. Kanunnikova

Omsk State Medical University

Email: lesia.tch@yandex.ru
ORCID iD: 0009-0003-3721-4379

Associate Professor, Department of Internal Medicine and Family Medicine of Postgraduate Education

Russian Federation, Omsk

Olga Yu. Korennova

Clinical Cardiology Dispensary

Email: korennova@mail.ru
ORCID iD: 0000-0001-8047-5521

Dr. Sci. (Med.), Professor, Professor at the Department of Internal Medicine and Family Medicine of Postgraduate Education, Chief Physician

Russian Federation, Omsk

Svetlana P. Podolnaya

Clinical Cardiology Dispensary

Email: podolnayasvetlana@mail.ru
ORCID iD: 0000-0002-2059-7727

Cand. Sci. (Med.), Deputy Chief Physician for Outpatient and Polyclinic Work

Russian Federation, Omsk

Tatyana Yu. Klepatskaya

Clinical Cardiology Dispensary

Email: omskcardio@yandex.ru

Head of Laboratory Department

Russian Federation, Omsk

Irina D. Kalinina

Omsk State Medical University

Email: irinka_9219@mail.ru

2nd year resident in the specialty of endocrinology, Department of Internal Medicine and Family Medicine of Postgraduate Education

Russian Federation, Omsk

References

  1. Zheng Y., Ley S.H., Hu F.B. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98. doi: 10.1038/nrendo.2017.151.
  2. Дедов И.И., Шестакова М.В., Викулова О.К. и др. Сахарный диабет в Российской Федерации: динамика эпидемиологических показателей по данным Федерального регистра сахарного диабета за период 2010–2022 гг. Сахарный диабет. 2023;26(2):104–123. [Dedov I.I., Shestakova M.V., Vikulova O.K., et al. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Diabetes Mellitus. 2023;26(2):104–123. (In Russ.)]. doi: 10.14341/DM13035.
  3. Kang S., Verma S., Hassanabad A.F., et al. Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results. Can J Cardiol. 2020;36(4):543–553. doi: 10.1016/j.cjca.2019.08.033.
  4. Verma S., McMurray J.J.V. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108-2117. doi: 10.1007/s00125-018-4670-7.
  5. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 11-й выпуск. М., 2023. [Algorithms of specialized medical care for patients with diabetes mellitus. Edited by I.I. Dedov, M.V. Shestakova, A.Yu. Mayorov. 11th issue. Moscow, 2023. (In Russ.)]. doi: 10.14341/DM13042.
  6. Сафронова С.С., Друк И.В., Горощеня О.И. Характеристика сахароснижающей терапии в группе пациентов с сахарным диабетом 2 типа и артериальной гипертензией молодого и среднего возраста в реальной клинической практике. Терапия. 2023;9(S7 (69);256. [Safronova S.S., Druk I.V., Goroschenya O.I. Characteristics of hypoglycemic therapy in a group of patients with type 2 diabetes mellitus and arterial hypertension of young and middle age in real clinical practice. Therapy. 2023;9(S7 (69);256. (In Russ.)].
  7. Колбин А.С., Курылев А.А., Балыкина Ю.Е., Проскурин М.А. Фармакоэкономическая оценка ипраглифлозина в комбинации с метформином в сравнении с другими режимами терапии сахарного диабета 2 типа. Качественная клиническая практика. 2020;5:50–63. [Kolbin A.S., Kurylev A.A., Balykina Yu.E., Proskurin M.A. Pharmacoeconomic evaluation of ipragliflozin in combination with metformin in comparison with other regimens of therapy for type 2 diabetes mellitus. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2020;(5):50–63. (In Russ.)]. doi: 10.37489/2588-0519-2020-5-50-63.
  8. Nagueh S.F., Smiseth O.A., Appleton C.P., et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016;29(4):277–314. doi: 10.1016/j.echo.2016.01.011.
  9. Otto C.M. The practice of clinical echocardiography. 5tn ed. Philadelphia, Pennsylvania: Elsevier, 2016. 1024 р.
  10. Жерко О.М. Эхокардиографические критерии диастолической дисфункции левого желудочка и их диагностическая надежность. Вестник Витебского государственного медицинского университета. 2020;3:87–95. Zherko O.M. Echocardiographic criteria of left ventricular diastolic dysfunction and their diagnostic reliability. Vestnik Vitebskogo gosudarstvennogo meditsinskogo universiteta. 2020;3:87–95. (In Russ.)]. doi: 10.22263/2312-4156.2020.3.87.
  11. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. [Chronic heart failure. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ.)]. doi: 10.15829/1560-4071-2020-4083.
  12. Галявич А.С., Терещенко С.Н., Ускач Т.М. и др. Хроническая сердечная недостаточность. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(11):6162. [Galyavich A.S., Tereshchenko S.N., Uskach T.M. et al. Chronic heart failure. Clinical guidelines 2024. Russian Journal of Cardiology. 2024;29(11):6162. (In Russ.)]. doi: 10.15829/1560-4071-2024-6162.
  13. Бубнова М.Г., Персиянова-Дуброва А.Л. Применение теста с шестиминутной ходьбой в кардиореабилитации. Кардиоваскулярная терапия и профилактика. 2020;19(4):2561. [Bubnova M.G., Persiyanova-Dubrova A.L. Six-minute walk test in cardiac rehabilitation. Cardiovascular Therapy and Prevention. 2020;19(4):2561. (In Russ.)]. doi: 10.15829/1728-8800-2020-2561.
  14. Никитин С.С., Куцев С.И., Басаргина Е.Н. и др. Клинические рекомендации по оказанию медицинской помощи пациентам с болезнью Помпе. Нервно-мышечные болезни. 2016;1:11–43. [Nikitin S.S., Kutsev S.I., Basargina E.N. et al. Clinical guidelines for providing medical care to patients with Pompe disease. Neuromuscular diseases. 2016;1:11–43. (In Russ.)].
  15. Morisky D.E., Ang A., Krousel-Wood M., Ward H.J. Predictive validity of a medication adherence measure in an outpatient setting. Journal of clinical hypertension (Greenwich) 2008;10(5):348–54. doi: 10.1111/j.1751-7176.2008.07572.x.
  16. Лукина Ю.В., Марцевич С.Ю., Кутишенко Н.П. Шкала Мориски–Грина: плюсы и минусы универсального теста, работа над ошибками. Рациональная фармакотерапия в кардиологии. 2016;12(1):63–65. [(In Russ.)]. doi: 10.20996/1819-6446-2016-12-1-63-65.
  17. Николаев Н.А., Мартынов А.И., Скирденко Ю.П. и др. Приверженность в клинической практике. Международное методическое руководство. Москва, 2023. [Nikolaev N.A., Martynov A.I., Skirdenko Yu.P. et al. Adherence in clinical practice. International methodological guidelines. Moscow, 2023. (In Russ.)].
  18. Suzuki Y., Kaneko H., Okada A., et al. Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus. Cardiovasc Diabetol. 2022;21(1):67. doi: 10.1186/s12933-022-01508-6.
  19. Shao S.C., Chang K.C., Lin S.J., et al. Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease. Cardiovasc Diabetol. 2021;20:213. doi: 10.1186/s12933-021-01406-3.
  20. Wei X.B., Wei W., Ding L.L., et al. Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: a network meta-analysis of large randomized trials. Prim Care Diabetes. 2021;15:208–211. doi: 10.1016/j.pcd.2020.08.017.
  21. Друк И.В., Сафронова С.С., Канунникова О.И. Причины формирования и сложности диагностики сердечной недостаточности у пациентов с сахарным диабетом 2 типа. Международный журнал сердца и сосудистых заболеваний. 2024;12(44):54–63. [Druk I.V., Safronova S.S., Kanunnikova O.I. Causes of formation of heart failure and difficulties in its diagnosing in patients with type 2 diabetes mellitus. International Journal of Heart and Vascular Diseases. 2024;12(44):54–63. (In Russ.)]. doi: 10.24412/2311-1623-2024-44-54-63.
  22. Cai X., Ji L., Chen Y., et al. Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: A meta-analysis. J Diabetes Investig. 2017;8(4):510–517. doi: 10.1111/jdi.12625.
  23. Elgebaly A., Abdelazeim N., Abdelazeim B., et al. Tolerability and efficacy of ipragliflozin in the management of inadequately controlled type 2 diabetes mellitus: a systematic review and meta-analysis. ExpClin Endocrinol Diabetes. 2021;129(1):56–72. doi: 10.1055/a-0579-7860.
  24. Shestakova M.V., Wilding J.P.H., Wilpshaar W., et al. A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus. Diabetes Res Clin Pract. 2018;146:240–250. doi: 10.1016/j.diabres.2018.10.018.
  25. Kashiwagi A., Kazuta K., Goto K., et al. Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2015;17(3):304–308. doi: 10.1111/dom.12331.
  26. Lan N.S.R., Fegan P.G., Yeap B.B., Dwivedi G. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions. ESC Heart Fail. 2019;6(5):927-935. doi: 10.1002/ehf2.12505.
  27. Requena-Ibáñez J.A., Santos-Gallego C.G., Rodriguez-Cordero A., et al. Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF: From the EMPA-TROPISM Study. JACC Heart Fail. 2021;9(8):578–589. doi: 10.1016/j.jchf.2021.04.014.
  28. Nassif M.E., Windsor S.L., Tang F., et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction. Circulation. 2019;140:1463–76. doi: 10.1161/CIRCULATIONAHA.119.042929.
  29. Ferrannini E., Baldi S., Frascerra S., et al. Renal handling of ketones in response to sodium–glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care. 2017;40:771–6. doi: 10.2337/dc16-2724.
  30. Heerspink H.J.L., de Zeeuw D., Wie L., et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15:853–62. doi: 10.1111/dom.12127.
  31. Verma S., Mazer C.D., Yan A.T., et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease. Circulation. 2019;140:1693–702. doi: 10.1161/CIRCULATIONAHA.119.042375.
  32. Januzzi J.L., Butler J., Jarolim P., et al. Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. J Am Coll Cardiol. 2017;70:704–12. doi: 10.1016/j.jacc.2017.06.016.
  33. Tanaka A., Hisauchi I., Taguchi I., et al. Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE). ESC Heart Fail. 2020;7:1585–94. doi: 10.1002/ehf2.12707.
  34. Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium–glucose cotransporter 2 inhibitors. Milton Packer. First published: 10 February 2020. doi: 10.1002/ejhf.1732.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Bionika Media